CO5390084A1 - Complejo que comprende factor inhibidor de osteoclastoge- nesis y polisacarido - Google Patents

Complejo que comprende factor inhibidor de osteoclastoge- nesis y polisacarido

Info

Publication number
CO5390084A1
CO5390084A1 CO02056452A CO02056452A CO5390084A1 CO 5390084 A1 CO5390084 A1 CO 5390084A1 CO 02056452 A CO02056452 A CO 02056452A CO 02056452 A CO02056452 A CO 02056452A CO 5390084 A1 CO5390084 A1 CO 5390084A1
Authority
CO
Colombia
Prior art keywords
ocif
group
further characterized
substance selected
complex according
Prior art date
Application number
CO02056452A
Other languages
English (en)
Inventor
Yamamoto Shinichi
Okada Junichi
Kurihara Atsushi
Numazawa Taku
Kondo Junichi
Tsuda Eisuke
Mochizuki Shinishi
Nishi Hirotaka
Miyazaki Hideki
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of CO5390084A1 publication Critical patent/CO5390084A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un complejo que comprende por lo menos una sustancia seleccionada del grupo que consiste de factor inhibidor de osteoclastogénesis (OCIF), análogos del mismo y variantes del mismo, caracterizado porque se une a por lo menos una sustancia seleccionada del grupo que consiste de polisacáridos y derivados de los mismos. El complejo de conformidad con la reivindicación 1, caracterizado además porque dicha sustancia seleccionada del grupo que consiste de OCIF, análogos del mismo y variantes del mismo, es de tipo natural o de tipo recombinante. El complejo de conformidad con las reivindicaciones 1 ó 2, caracterizado además porque dicha sustancia seleccionada del grupo que consiste de OCIF, análogos del mismo y variantes del mismo, es un monómero o un dímero. El complejo de conformidad con la reivindicación 3, caracterizado además porque dicha sustancia seleccionada del grupo que consiste de OCIF, análogos del mismo y variantes del mismo, es OCIF monomérico humano que tiene un peso molecular, medido mediante SDS-PAGE bajo condiciones no reductoras, de aproximadamente 60000, u OCIF dimérico humano que tiene un peso molecular de aproximadamente 120000, medido mediante SDS-PAGE bajo condiciones no reductoras. El complejo de conformidad con cualquiera de las reivindicaciones 1 a 4, caracterizado además porque dicho OCIF comprende los aminoácidos -21 a 380 de SEQ. ID. NO: 1 del listado de secuencias. El complejo de conformidad con cualquiera de las reivindicaciones 1 a 4, caracterizado además porque dicho OCIF comprende los aminoácidos 1 a 380 de SEQ. ID. NO: 1 del listado de secuencias.
CO02056452A 2001-06-29 2002-06-28 Complejo que comprende factor inhibidor de osteoclastoge- nesis y polisacarido CO5390084A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001198985 2001-06-29

Publications (1)

Publication Number Publication Date
CO5390084A1 true CO5390084A1 (es) 2004-04-30

Family

ID=19036337

Family Applications (1)

Application Number Title Priority Date Filing Date
CO02056452A CO5390084A1 (es) 2001-06-29 2002-06-28 Complejo que comprende factor inhibidor de osteoclastoge- nesis y polisacarido

Country Status (22)

Country Link
US (3) US20030045456A1 (es)
EP (1) EP1270015A3 (es)
KR (1) KR20030003124A (es)
CN (1) CN1442201A (es)
AR (1) AR034716A1 (es)
AU (1) AU783126B2 (es)
BR (1) BR0202439A (es)
CA (1) CA2392383A1 (es)
CO (1) CO5390084A1 (es)
CZ (1) CZ20022231A3 (es)
HK (1) HK1048762A1 (es)
HU (1) HUP0202119A2 (es)
IL (1) IL150448A0 (es)
MX (1) MXPA02006511A (es)
NO (1) NO20023144L (es)
PA (1) PA8549401A1 (es)
PE (1) PE20030254A1 (es)
PL (1) PL354799A1 (es)
RU (1) RU2232594C2 (es)
SG (1) SG98059A1 (es)
SK (1) SK9492002A3 (es)
ZA (1) ZA200205164B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
KR20010082272A (ko) 1998-10-28 2001-08-29 쇼노 카츄야 골대사이상증 치료제
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
TW200303757A (en) * 2002-03-01 2003-09-16 Sankyo Co A pharmaceutical composition
AU2003240754B2 (en) 2002-04-10 2009-02-26 Merck Serono Sa Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
US7585840B2 (en) * 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
WO2003103710A1 (ja) * 2002-06-07 2003-12-18 三共株式会社 骨破壊の治療または予防剤組成物の併用効果
KR100840830B1 (ko) * 2006-09-03 2008-06-23 재단법인서울대학교산학협력재단 고분자 히알루론산을 포함하는 골흡수 저해용 조성물
ITMI20121316A1 (it) * 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
CN115594776B (zh) * 2022-09-19 2024-03-15 山东大学 一种ROS响应性聚合物Mal-PHB-Dextran及细胞背包载药系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207A (en) * 1845-09-27 lewis
US181418A (en) * 1876-08-22 Improvement in gas apparatus
US31725A (en) * 1861-03-19 Improvement in cultivators
US45456A (en) * 1864-12-13 Improved apparatus for carbureting air
US216297A (en) * 1879-06-10 Improvement in ironing-stands
US139325A (en) * 1873-05-27 Improvement in carriage-springs
TW318142B (es) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
NZ335759A (en) * 1997-09-24 2002-02-01 Sankyo Co Method of diagnosing metabolic bone diseases by measuring osteoclastgenesis inhibitory factor (OCIF)
ATE230752T1 (de) * 1998-06-15 2003-01-15 Takeda Chemical Industries Ltd Thienodipyridinderivate, ihre herstellung und verwendung
KR20010082272A (ko) * 1998-10-28 2001-08-29 쇼노 카츄야 골대사이상증 치료제
IL142900A0 (en) * 1999-09-03 2002-04-21 Amgen Inc Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
AU2001295850A1 (en) * 2000-09-28 2002-04-08 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
TW200303757A (en) * 2002-03-01 2003-09-16 Sankyo Co A pharmaceutical composition

Also Published As

Publication number Publication date
CZ20022231A3 (cs) 2003-02-12
RU2002117385A (ru) 2004-01-27
US20060084595A1 (en) 2006-04-20
EP1270015A2 (en) 2003-01-02
KR20030003124A (ko) 2003-01-09
PL354799A1 (en) 2002-12-30
RU2232594C2 (ru) 2004-07-20
IL150448A0 (en) 2002-12-01
SG98059A1 (en) 2003-08-20
AU5071902A (en) 2003-01-02
ZA200205164B (en) 2003-03-24
HK1048762A1 (zh) 2003-04-17
US20030045456A1 (en) 2003-03-06
PE20030254A1 (es) 2003-03-19
BR0202439A (pt) 2003-06-10
NO20023144D0 (no) 2002-06-28
CN1442201A (zh) 2003-09-17
EP1270015A3 (en) 2004-02-25
NO20023144L (no) 2002-12-30
CA2392383A1 (en) 2002-12-29
HU0202119D0 (es) 2002-08-28
HUP0202119A2 (hu) 2003-04-28
AU783126B2 (en) 2005-09-29
PA8549401A1 (es) 2003-07-28
US20030139325A1 (en) 2003-07-24
AR034716A1 (es) 2004-03-17
MXPA02006511A (es) 2004-08-11
SK9492002A3 (en) 2003-02-04

Similar Documents

Publication Publication Date Title
CO5390084A1 (es) Complejo que comprende factor inhibidor de osteoclastoge- nesis y polisacarido
ES2406090T3 (es) Péptidos que tienen actividad farmacológica para tratar los trastornos asociados con la alteración de la migración celular, tal como el cáncer
Tuszynski et al. Biological activities of peptides and peptide analogues derived from common sequences present in thrombospondin, properdin, and malarial proteins.
DK0861261T3 (da) Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå
AU748134B2 (en) Integrin binding peptide and use thereof
Kosfeld et al. Identification of a new cell adhesion motif in two homologous peptides from the COOH-terminal cell binding domain of human thrombospondin.
PE7898A1 (es) Peptidos compuestos que se ligan al receptor de trombopoietina
ES2175937T3 (es) Composiciones detergentes para lavavajillas que contienen diaminas organicas.
ATE113063T1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
RU99106518A (ru) Glp-1 производные
NI200900158A (es) Coagonistas de receptor de glucagón/glp-1
AR039231A1 (es) Agentes de union ox40r novedosos
DK1326634T3 (da) Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber
NO20092774L (no) HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette
EA011037B1 (ru) Олигомерные пептиды и их применение для лечения вич инфекций
Han et al. Preparation and applications of xanthenylamide (xal) handles for solid-phase synthesis of c-terminal peptide amides under particularly mild conditions1-3
EA200000379A1 (ru) Усеченные по амино-концу rantes как антагонисты хемокинов
WO2018175534A1 (en) Npra agonists, compositions, and uses thereof
PT1797112E (pt) Inibidores do vírus da hepatite c
CA2126212A1 (en) A novel molecule which inhibits neuropeptide tyrosine biological function
US20080171697A1 (en) Peptides Having For Example Antiangiogenic Activity and Applications Thereof In Therapeutics
AR022395A1 (es) PEPTIDOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFAvBETA6, LOS MEDICAMENTOS A BASE DE ESTOS PEPTIDOS, LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS PEPTIDOS, EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO, SECUENCIAS DE ADN RECOMBINANTE QUE CODIFICAN PARA UN FRA
JP2008505848A (ja) 血管新生阻害剤、それらを含む組成物及び血管新生障害に関連する疾患の治療におけるそれらの使用
AR124475A1 (es) Conjugados anticuerpo-droga mejorados dirigidos contra cd30 y usos de los mismos
EP1328539A1 (en) Vegf peptides and their use for inhibiting angiogenesis